Form D · Biotechnology
SightStream Biotherapeutics, Inc.
Walpole, MA · CIK 0001932386
Offering snapshot reported Oct 16, 2025 · SEC filing
- Reported sold
- $1.79M Offering amount: $1.79M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 2, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 16, 2025 | Initial | $1,791,165 | No comparison | 9 | SEC filing |
| Aug 25, 2023 | Initial | $250,000 | No comparison | 2 | SEC filing |
| Jun 12, 2023 | Amendment | $3,065,000 | $150,000vs Mar 1, 2023 | 21 | SEC filing |
| Mar 1, 2023 | Amendment | $2,915,000 | $1,015,000vs Jun 3, 2022 | 19 | SEC filing |
| Jun 3, 2022 | Initial | $0 | No comparison | 18 | SEC filing |
| Jun 3, 2022 | Initial | $1,900,000 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-561030
Simple Agreement for Future Equity
Source: Form D, filed Oct 16, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Reza Dana | Director |
| David Neafus | Executive |
| Jason Werner | Director, Executive |
| Samuel Wu | Director |
| Wenkai Xiang | Director |
| Jiagang Zhao | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
55 West Street, Suite 201
Walpole, MA, 02081
Walpole, MA, 02081